420 with CNW — Canadian Cannabis Executives Share Their Industry Policy Reform Wishlists for 2022

Last year was a mixed bag of a year for Canadian marijuana investors. Speculation about the future of the sector fluctuated wildly as talks about federal legalization heated up in the United States and recreational cannabis prices reached historic lows. Additionally, players in the Canadian cannabis space are waiting with bated breath for the three-year review of the country’s cannabis legislation by federal lawmakers. The review began in December 2021, and the health minister will present the department’s findings and recommendations in 2023.

In the interim, industry leaders have a few policy changes in mind that they would like to see in 2022. George Smitherman, president and CEO of the Cannabis Council of Canada, would like stronger edible products allowed on the market. Currently, cannabis law limits potency to 10 mg of THC per packaged product. In comparison, California allows for 100 mg of THC per package. Smitherman also feels it would be beneficial if customers could buy more cannabis-infused beverages in a single package because as the 28-gram possession limit for THC prevents them from purchasing more than five beverages.

Another change would allow producers to sell their dried cannabis flower in packaging that isn’t childproof to reduce the amount of single-use plastics they use. Since cannabis flower presents a significantly reduced ingestion risk to children compared to candy, using nonchildproof packaging would also be safe.

However, the biggest challenge the industry faces right now is falling recreational cannabis prices, says Smitherman. Although prices are designed to draw customers from the illicit market, they have had a major impact on producers’ bottom lines.

Lawmakers can ease the pressure off producers by adjusting excise tax rates. Mandesh Dosanjh, president and CEO of Pure Sunfarms, would like a reform of the industry’s excise tax rules. Rather than a fixed or flat rate, he says, the government ought to change the tax to a more manageable percentage. As of December 10, cannabis sales are taxed at $4.97 per gram.

Dosanjh also criticized the country’s inconsistent lab testing standards, which often end up with different results for the same product. This has allowed some producers to test their products in different labs and then use the result with the highest cannabinoid value, which often translates to higher prices.

Niel Marotta, president and CEO of Indiva, would like to see an increase in potency limits for edibles. He also hopes that Quebec’s government will remove its ban on edibles and vape products. Low prices are also a point of contention, he says, although his company is more insulated because it deals with edibles rather than cannabis flower. Marotta hopes to be able to break into the restaurant industry one day with a variety of cannabis-infused edibles, including salt and sugar.

If the long-overdue changes are made to the regulations governing edibles and cannabis drinks, we could see an explosion in the demand for the products of Canada-based companies, including BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC).

NOTE TO INVESTORS: The latest news and updates relating to BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) are available in the company’s newsroom at http://cnw.fm/BVNNF

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Study Explores Why Individuals Use Marijuana During Pregnancy or While Lactating

A new study has found that people who use marijuana during lactation or pregnancy use it to manage pre-existing conditions such as insomnia and mental health conditions, as well as pregnancy-related symptoms, including nausea and vomiting.

Dr. Meredith Vanstone, one of the authors of the study, stated that their findings didn’t resonate as much with evidence on motives for marijuana use that have been identified in nonpregnant populations, which proposed that reasons for the herb’s use during lactation and pregnancy were unique.

Vanstone explained that the reasons for the herb’s use that had been provided by the study’s participants closely resembled those cited in research on the use of medical marijuana, noting that most participants used the herb to manage more than one symptom. These reasons included to manage nausea or boost appetite, for sleep, and to control muscle spasms and pain as well as manage depression and anxiety.

For their study, the researchers recruited 52 individuals from Canada, one of whom identified as nonbinary. Each individual who was recruited had used marijuana prior to their pregnancy. At the time of their interviews, 22 of them were breastfeeding while the remaining were pregnant. Every individual was asked to give reasons why they used cannabis, with researchers finding that these reasons changed when some became pregnant. For instance, some stopped using cannabis due to health reasons, guilt and social stigma while others stopped out of fear of harming the fetus.

Those who continued to use cannabis after finding out that they were pregnant discussed their motive as associated with managing symptoms of conditions that existed prior to the pregnancy, as well as pregnancy symptoms. The researchers found that after giving birth, the reasons some participants gave for using marijuana changed again to closely resemble the motives they gave for using the herb before they became pregnant.

The study’s findings have implications for clinical practice, which include counselling of lactating and pregnant individuals on the possible harms of using marijuana and alternative approaches. In the conclusion, Vanstone noted that it was important for doctors to understand that individuals who use marijuana during pregnancy often did so because they recognized the benefits of marijuana for controlling various symptoms. Vanstone highlighted that there existed an opportunity to help pregnant individuals find alternatives that were safe for both the mother and the child, while looking into the benefits that these individuals derived from marijuana.

The study’s findings were reported in the “Canadian Medical Association Journal.”

As more information becomes available regarding the reasons why various categories of people consume the marijuana products made by companies such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF), policymakers will be in a better position to enact laws that are relevant to the present and future generations.

NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Marijuana Company of America Inc. (MCOA) Carving out Market Share, Tapping Strategic Partnerships

Marijuana Company of America (OTC: MCOA) recently released financial results for the three months ended Sept. 30, 2021 (“Q3 2021”), posting a 731% year-on-year increase compared to the same period in Q3 2020. Total revenue stood at $442,178 (up from $53,195), with gross profit to $63,687, up from $16,025 in Q3 2020, representing a 297% increase over that period. MCOA has attributed the impressive growth to its new acquisition of cDistro, a distribution enterprise, which positioned it to take advantage of immediate revenue granted by the opportunity to carve out a significant market share in the specialty distribution space. In addition to acquisitions, MCOA has also tapped into strategic industry partnerships with Cannabis Global Inc. (OTC: CBGL), Eco Innovation Group Inc. (OTC: ECOX), and Natural Plant Extract to push its growth. “We are confident that the steps we are taking will enable us to maintain a growing strong position as we drive growth across the entire business and maximize value for our shareholders over the long term,” commented Jesus Quintero, the CEO of MCOA.

To view the full article, visit https://cnw.fm/AWpNe

About Marijuana Company of America Inc.

Marijuana Company of America operates and invests in the cannabis sector directly. The company’s operations include C-Distro, one of the fastest growing distribution companies in the THC, Hemp and CBD cannabis industries, and hempsmart(TM), a premium CBD company. The company’s core mission is to leverage its experience and access to capital to identify and invest in acquisitions with unique growth potential. For more information, visit www.MarijuanaCompanyofAmerica.com.

NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://cnw.fm/MCOA

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Federal Agency Announces Funding for Research into Drug-Harm-Reduction Approaches

The National Institutes of Health is promoting research into the effectiveness of various harm-reduction strategies, which include safe consumption facilities and drug decriminalization, as part of its effort to fight the opioid epidemic. The federal health agency released requests for applications last week for an effort that will generate funding for studies on how safe consumption sites and other harm-reduction strategies can be used to address the overdose crises.

The agency seeks to launch a Harm Reduction Network that will grow the understanding of the implementation, impact and effectiveness of new and existing harm-reduction strategies in order to address substance use disorder and the opioid epidemic more broadly.

A counterpart request for application requests the establishment of a coordination center in the network, which will offer coordination and logistical support, clinical practice and research resources, data sharing and data harmonization supports.

The agency is accepting applications for projects that entail the expansion of the delivery models and settings through which harm-reduction policies are established; the development and testing of new harm-reduction practices; the assessment of the impact of new harm-reduction strategies that have been implemented at the local and state levels; and implementation of new and existing harm-reduction policies effectively.

In its notice, the agency states that harm-reduction strategies are aimed at minimizing or preventing adverse outcomes associated with substance use, including the transmission of infectious diseases as well as nonfatal and fatal overdoses. The ageny highlights examples of existing harm-reduction services, which include HIV and Hepatitis C virus testing, sterile syringes, safer smoking equipment, fentanyl test strips and naloxone.

This is in addition to noting that the Office of National Drug Control Policy is focused on the prioritization of harm-reduction policy, as a way to prevent overdoses.

Component agencies of the NIH, including the National Institute on Drug Abuse, state that emerging harm-reduction strategies include the authorization of safe consumption facilities, prosecutor and police-driven diversion and deflection efforts, and the decriminalization of certain drugs.

Nora Volkow, director of NIDA, has repeatedly voiced concerns about the harms caused by drug criminalization. Last year, Volkow revealed that she was open to exploring how support systems could help individuals obtain treatment, hinder them from getting infected with HIV, and prevent overdoses and death.

In November 2021, the city of New York established the first safe consumption facility in the country. Advocates wonder how the government will react to this, as it recently blocked Safehouse, a not-for-profit in Philadelphia, from establishing a harm-reduction facility.

There is hope that such federally backed studies could tilt the tide in favor of ending prohibition so that more people can enjoy the benefits of various innovative products such as the RYAH Smart Inhaler from RYAH Group Inc. (CSE: RYAH) intended to bring precision to the measurement of plant medicine doses.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — A Recap of Top Cannabis Stories of 2021

Another year has drawn to a close. For many, 2021 was a mixed bag of a year — we were still grappling with the effects of the coronavirus pandemic, but the global supply chain and economy was starting to show signs of recovery. The year brought a variety of wins to America’s cannabis industry, even though some events may not have seemed like wins at the time. For instance, the controversial suspension of American sprinter Sha’Carri Richardson due to a positive THC test sparked an intense review of cannabis policy. Here is an overview of what happened to cannabis in 2021.

Several states legalized cannabis last year. New York State passed a bill that would allow adults 21 and older to purchase and possess cannabis as well as decriminalize the possession of up to three ounces of cannabis or 24 grams of concentrates. This bill would also expunge certain cannabis offenses from people’s records and provide a variety of protections for people who work in the marijuana industry or consume cannabis. In Virginia, lawmakers passed a bill to legalize cannabis possession and home cultivation. Cannabis-related arrests, charges, and convictions would be sealed away from public view.

New Mexico also joined the cannabis train, passing a law that would allow adults 21 and older to possess up to 16 grams of concentrates, two ounces of cannabis and 800 milligrams of infused edibles; they would also be allowed to grow up to six mature plants at home. Connecticut passed a cannabis law in June 2021, allowing for the possession of up to 1.5 ounces of cannabis and minimizing punishments levied on those between 18—20 who are found possessing cannabis. Retail cannabis sales for adults 21 and over will begin in 2023.

Alabama also joined the increasing number of states with cannabis laws, passing a medical marijuana bill that would allow patients with any of 20 qualifying conditions to use medical marijuana. Louisiana passed a marijuana decriminalization bill that would bring down the penalty for possessing up to 14 grams of cannabis to a $100 fine. According to Governor John Bel Edwards, there’s a chance this modest reform could result in broad legalization.

Lawmakers also made significant moves at the federal level. For starters, Senate Majority Leader Chuck Schumer and some congressional colleagues introduced a bill dubbed the Cannabis Administration and Opportunity Act that would federally decriminalize cannabis. The bill would also expunge past convictions and allow states to craft their own cannabis policies. A key House committee passed a federal legalization bill that would promote social equity, but cannabis banking legislation failed to reach the finish line.

One of the most surprising events of 2021 was a GOP lawmaker unveiling an alternative federal legalization plan that would essentially treat cannabis like alcohol. Last year also saw safe consumption sites gain traction, with sites in New York preventing dozens of overdoses deaths.

California, currently the largest cannabis market in the U.S., has also enacted its own reforms to further streamline the marketplace in which entities such as Simply Sonoma Inc. operate.

NOTE TO INVESTORS: The latest news and updates relating to Simply Sonoma Inc. are available in the company’s newsroom at https://cnw.fm/Sonoma

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Expands White-Label Program to Add Averi Health Products

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health and wellness beverage and natural products company, recently entered into an agreement to manufacture and distribute white-label cannabis beverages for Averi Health Products. An emerging alternative beverage company, Averi Health Products was founded by Terry Donnelly, former CEO of the award-winning Hill Street Beverage Co. Catering to millennials’ changing preferences, with many choosing to consume less alcohol than preceding generations, Averi is focused on creating cannabis and hemp-infused adult beverage options directed at consumers with a discerning palate, who are unwilling to compromise on taste, complexity, sophistication or social experience. “Averi is a great example of this next generation of beverage creators that are coming to BevCanna to bring its cannabis-infused concepts to life,” a recent article quotes BevCanna President Melise Panetta as saying. “Our white-label program gives these brands confidence that its beverages will be produced to the highest quality standards and widely distributed through our extensive Canadian network.”

To view the full article, visit https://cnw.fm/dK2SZ

About BevCanna Enterprises Inc.

BevCanna Enterprises is a diversified health and wellness beverage and natural products company. BevCanna develops and manufactures a range of alkaline, plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. With decades of experience creating, manufacturing and distributing iconic brands that resonate with consumers on a global scale, the team demonstrates an expertise unmatched in the nutraceutical and cannabis-infused beverage categories. Based in British Columbia, Canada, BevCanna owns a pristine alkaline spring water aquifer and a world–class 40,000–square–foot, HACCP-certified manufacturing facility, with a bottling capacity of up to 210M bottles annually. BevCanna’s extensive distribution network includes more than 3,000 points of retail distribution through its market-leading TRACE brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network, and a partnership with top U.S. cannabis beverage company Keef Brands. For more information about the company, visit www.BevCanna.com.

NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://cnw.fm/BVNNF

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – VPR Brands LP (VPRB) Announces Settlement of Second Patent Infringement Case

VPR Brands (OTC: VPRB) is a market leader and pioneer in electronic cigarettes and vaporizers for nicotine, cannabis and cannabidiol (“CBD”). The company owns intellectual property, which is one of the original patents filed for electronic cigarette technology. Dating to 2009, the patent includes independent claims covering electronic cigarette products containing an electric airflow sensor, including a sensor comprised of a diaphragm microphone. The technology, covered under electronic cigarette utility patent US 8,205,622, includes an airflow sensor that turns the battery on and off and covers most auto-draw, button less e-cigarettes, cig-a-likes, pod devices and vaporizers. According to the update, the patent case filed in United States District Court Central District of California Los Angeles Division, VPR BRANDS LP V. PHD MARKETING INC, was settled with both defendants for a total sum of $85,000 to be paid to VPR Brands LP. “I want to once again thank our legal team at SRIPLAW for their hard work and diligence in settling this matter,” said Kevin Frija, CEO of VPR Brands. “As I have said before, it is a win-win for all parties when a dispute can be settled ahead of trial.”

To view the full press release, visit https://cnw.fm/3Ilks

About VPR Brands LP

VPR Brands is a technology company, whose assets include issuing U.S. and Chinese patents for atomization-related products including technology for cannabis, medical marijuana, hemp and electronic cigarette products and components as well as lighters specifically used for cannabis and pipe tobacco. The company is also engaged in product development for the vapor or vaping market, including e-liquids, vaporizers and electronic cigarettes (also known as e-cigarettes), which are devices that deliver nicotine and or cannabis through atomization or vaping and without smoke and other chemical constituents typically found in traditional products. For more information about the company, visit www.VPRBrands.com.

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Agreements Totaling $11.5M for Gross Proceeds

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system (“CNS”), has entered into securities purchase agreements with several institutional and accredited investors. The agreements outline the issue of more than 12 million shares of common stock, prefunded warrants and warrants in a private placement; the shares and warrants are offered at a purchase price of $0.95 per share. The issuance will result in an estimated $11.5 million gross proceeds for the company. Anticipated closing of the private placement is expected on or about Jan. 10, 2022, assuming customary closing conditions are met. CNSP will use the funds to support its clinical trials and preclinical programs as well as other R&D activities and general corporate purposes. According to the announcement, the transaction does not involve a public offering and the securities are not registered under the Securities Act of 1933 or applicable state securities laws, which means the securities cannot be offered in the United States without including an effective registration statement or applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.

To view the full press release, visit https://ibn.fm/V47iX

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces Strategic Advisory Board Appointment

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, today announced the appointment of accomplished business leader and cannabis industry expert Tim Leslie as the chairman of its newly formed advisory board. Establishment of the advisory board comes as Flora continues to develop its corporate structure to include a robust roster of human capital. Leslie’s appointment aligns with the company’s goal of working with the industry’s best leaders to provide strategic counsel on matters that will fuel its growth. “We are pleased and honored to have Tim join us as the first chairman of our advisory board,” said Luis Merchan, president and CEO of Flora Growth. “Tim’s extensive resume of leading the growth of prominent companies and projects and his deep understanding of the cannabis industry make Tim the ideal candidate for this role. We will look to our newly established advisory board for counsel on how to amplify our growth opportunities both domestically and internationally. Tim will play a key role in advising on how best to navigate the regulatory framework of building a truly global company, something he specifically worked on in his time at Amazon. All in all, we could not have asked for a more qualified person to fill the role of chairman and we truly thank Tim for his commitment to Flora and his belief in our mission and success.”

To view the full press release, visit https://cnw.fm/NtnGn

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands delivering the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Germany’s Marijuana Industry Soars as Country Prepares to Legalize Recreational Use

Last month, Germany’s new coalition government revealed that it planned to legalize marijuana for recreational use. This announcement has catapulted the country’s budding marijuana industry to new highs, with companies involved in the market now focusing on growing.

CEO Synbiotic is one of the companies that would like to establish a chain of dispensaries which would offer a full array of cannabis-related products — everything from edible gummies and flower to tinctures. The company is a major player in the country’s nascent cannabinoid sector, investing in everything from researchers to cultivators and distributors.

Many believe that legalization would be a game-changer for the international business of growing and selling cannabis. If the plan is actualized, the country would join Uruguay and Canada, which are the only countries that allow the commercial sale of recreational marijuana. Apart from the two nations, a number of states in the United States have also legalized the recreational use and sale of marijuana.

Demecan managing director Constantin von der Groeben stated that the herb’s legalization would make Germany the biggest country to allow the sale of marijuana globally, in terms of population. Demecan is the sole independent company authorized to produce medical marijuana in Germany. It is involved in every process of manufacturing marijuana, from growing and processing to storage and delivery.

Germany legalized the use of marijuana for medicinal purposes in 2017.

While the government’s intentions on legalization are still unclear, the three coalition partners revealed that fiscal arguments played a role in their decision to legalize the plant. Findings from a recent study show that decriminalization could deliver net benefit of more than €4.5 billion ($5.1 billion) to the state annually. This figure was inclusive of about €1.3 billion ($1.47 billion) in savings on legal costs and police costs and roughly €2.8 billion ($3.17 billion) in tax revenue.

The announcement also triggered increased interest in the sector, which skeptics believe will subside just as quickly. Some give the example of Canada where excitement about cannabis legalization in 2018 faded after the market’s growth fell short of expectations.

However, this boom and bust may not occur in Germany, as barriers to entry remain high. Only three firms in the country have a license to grow the plant: Demecan, Aurora and Aphria, with the last two being subsidiaries of Canadian companies. The companies are all required to adhere to a good manufacturing practice (“GMP”) standard, which is a globally standard for pharmaceutical products.

For cannabis companies such as Flora Growth Corp. (NASDAQ: FLGC) that are keeping an eye on the international market, the news out of Germany brings hope that a lot more countries could soon open their markets to marijuana and avail growth opportunities for established companies in that industry.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.